JW Pharmaceutical Corporation

KOSE:A001060 Stock Report

Market Cap: ₩593.6b

JW Pharmaceutical Balance Sheet Health

Financial Health criteria checks 6/6

JW Pharmaceutical has a total shareholder equity of ₩303.8B and total debt of ₩109.2B, which brings its debt-to-equity ratio to 35.9%. Its total assets and total liabilities are ₩636.9B and ₩333.1B respectively. JW Pharmaceutical's EBIT is ₩97.4B making its interest coverage ratio 18.5. It has cash and short-term investments of ₩95.9B.

Key information

35.9%

Debt to equity ratio

₩109.17b

Debt

Interest coverage ratio18.5x
Cash₩95.91b
Equity₩303.77b
Total liabilities₩333.11b
Total assets₩636.88b

Recent financial health updates

JW Pharmaceutical (KRX:001060) Seems To Use Debt Rather Sparingly

Aug 07
JW Pharmaceutical (KRX:001060) Seems To Use Debt Rather Sparingly

Is JW Pharmaceutical (KRX:001060) Using Too Much Debt?

Feb 15
Is JW Pharmaceutical (KRX:001060) Using Too Much Debt?

Recent updates

JW Pharmaceutical's (KRX:001060) Solid Earnings May Rest On Weak Foundations

Nov 23
JW Pharmaceutical's (KRX:001060) Solid Earnings May Rest On Weak Foundations

JW Pharmaceutical (KRX:001060) Seems To Use Debt Rather Sparingly

Aug 07
JW Pharmaceutical (KRX:001060) Seems To Use Debt Rather Sparingly

JW Pharmaceutical's (KRX:001060) Earnings Are Of Questionable Quality

Mar 21
JW Pharmaceutical's (KRX:001060) Earnings Are Of Questionable Quality

Is JW Pharmaceutical Corporation (KRX:001060) An Attractive Dividend Stock?

Apr 08
Is JW Pharmaceutical Corporation (KRX:001060) An Attractive Dividend Stock?

How Many JW Pharmaceutical Corporation (KRX:001060) Shares Do Institutions Own?

Mar 13
How Many JW Pharmaceutical Corporation (KRX:001060) Shares Do Institutions Own?

Is JW Pharmaceutical (KRX:001060) Using Too Much Debt?

Feb 15
Is JW Pharmaceutical (KRX:001060) Using Too Much Debt?

JW Pharmaceutical's(KRX:001060) Share Price Is Down 24% Over The Past Three Years.

Jan 19
JW Pharmaceutical's(KRX:001060) Share Price Is Down 24% Over The Past Three Years.

Do These 3 Checks Before Buying JW Pharmaceutical Corporation (KRX:001060) For Its Upcoming Dividend

Dec 24
Do These 3 Checks Before Buying JW Pharmaceutical Corporation (KRX:001060) For Its Upcoming Dividend

Would JW Pharmaceutical Corporation (KRX:001060) Be Valuable To Income Investors?

Nov 30
Would JW Pharmaceutical Corporation (KRX:001060) Be Valuable To Income Investors?

Financial Position Analysis

Short Term Liabilities: A001060's short term assets (₩361.0B) exceed its short term liabilities (₩254.8B).

Long Term Liabilities: A001060's short term assets (₩361.0B) exceed its long term liabilities (₩78.3B).

Debt to Equity History and Analysis

Debt Level: A001060's net debt to equity ratio (4.4%) is considered satisfactory.

Reducing Debt: A001060's debt to equity ratio has reduced from 77.3% to 35.9% over the past 5 years.

Debt Coverage: A001060's debt is well covered by operating cash flow (87.1%).

Interest Coverage: A001060's interest payments on its debt are well covered by EBIT (18.5x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 05:44
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

JW Pharmaceutical Corporation is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jisoo LeeDAOL Investment & Securities Co., Ltd.
Myung Sun LeeDB Financial Investment Co. Ltd.
Hyung Soo KimHanwha Investment & Securities Co., Ltd.